BackCanSino Biologics Overview

CanSino Biologics Receivables

Latest receivables for 6185.HK: $1B.

Get informed when a big investor buys or sells

+ Follow
Receivables
$1.01B
↑ 36.93% YoYΔ $272.37M vs prior year quarter

Peer trimmed avg / median

Loading

CanSino Biologics Receivables History

Loading

CanSino Biologics vs. peers: Receivables Comparison

Loading

CanSino Biologics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

CanSino Biologics (6185.HK) FAQ

CanSino Biologics's receivables stands at $1B as of September 2026. That compares with $740M in the prior-year period — up 36.9% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

CanSino Biologics reported $1B in receivables versus $740M a year earlier — a 36.9% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $740M in the prior-year period — up 36.9% year over year. Sustained growth in receivables can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how CanSino Biologics's receivables evolved across reporting periods, while the comparison chart places 6185.HK next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, receivables is commonly used to spot outliers. CanSino Biologics's reading of $1B is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.